Treatment for Subjects With Active Rheumatoid Arthritis (RA)
This study has been completed.
Information provided by (Responsible Party):
First received: May 16, 2005
Last updated: April 24, 2013
Last verified: April 2013
The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Open-Label Study to Assess the Safety of Etanercept Liquid Administered Once Weekly in Subjects With Active Rheumatoid Arthritis (RA)|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Amgen:
Primary Outcome Measures:
- Proportion of subjects having positive immunoassay response to etanercept liquid during the treatment period.
Secondary Outcome Measures:
- Incidence of adverse events, infectious episodes, serious adverse events, serious infectious episodes
- Measurements from safety laboratory assessments.
Contacts and Locations